Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Puromycin aminonucleoside (NSC-3056) 是一种氨基核苷类抗生素,是嘌呤霉素类似物。它可逆抑制二肽基肽酶和胞浆丙氨酸氨基肽酶。它通过以氧化应激依赖性方式调节 ZO-1 来增加足细胞通透性。它诱导细胞凋亡 。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 452 | 现货 | ||
10 mg | ¥ 617 | 现货 | ||
25 mg | ¥ 1,330 | 现货 | ||
50 mg | ¥ 2,560 | 现货 | ||
100 mg | ¥ 3,790 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | Puromycin aminonucleoside (NSC-3056) increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner. |
体外活性 | Puromycin aminonucleoside -induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside causes podocyte apoptosis in a time-dependent manner. The IC50 values for PMAT-expressing and vector-transfected cells are 48.9 and 122.1 μM, respectively, suggesting expression of PMAT-enhanced cell sensitivity to Puromycin aminonucleoside. Puromycin aminonucleoside uptake in PMAT-expressing cells is fourfold higher at pH 6.6 than that at pH 7.4. Puromycin aminonucleoside (30 μg/mL) markedly enhances p53 protein levels in podocytes. Puromycin aminonucleoside (250 μM) is toxic to both PMAT-expressing and vector-transfected cells [2][4]. |
体内活性 | Rats given Puromycin aminonucleoside (100 mg/kg, s.c.) gain less weight and their serum creatinine levels are higher than the control rats. The number of podocytes per glomerulus is 95.5±17.6 in the control rats, 90.7 on Day 4 in Puromycin aminonucleoside (8 mg/100 g, i.v.)-treated nephrosis rats. The amount of nephrin per glomerulus in control rats is 1.02±0.11 fmol and those in Puromycin aminonucleoside nephrosis rats are reduced to 0.46±0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte is significantly decreased association with the development of proteinuria in Puromycin aminonucleoside nephrosis rats [5][6]. |
别名 | 维生素E醋酸酯, NSC 3056 |
分子量 | 294.31 |
分子式 | C12H18N6O3 |
CAS No. | 58-60-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 33.33 mg/mL (113.25 mM), Sonification is recommended.
DMSO: 31 mg/mL(105.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 3.3978 mL | 16.9889 mL | 33.9778 mL | 84.9444 mL |
5 mM | 0.6796 mL | 3.3978 mL | 6.7956 mL | 16.9889 mL | |
10 mM | 0.3398 mL | 1.6989 mL | 3.3978 mL | 8.4944 mL | |
20 mM | 0.1699 mL | 0.8494 mL | 1.6989 mL | 4.2472 mL | |
50 mM | 0.068 mL | 0.3398 mL | 0.6796 mL | 1.6989 mL | |
100 mM | 0.034 mL | 0.1699 mL | 0.3398 mL | 0.8494 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Puromycin aminonucleoside 58-60-6 Apoptosis Metabolism Microbiology/Virology Proteases/Proteasome Ubiquitination Proteasome Aminopeptidase Antibacterial Antibiotic NSC-3056 Bacterial Inhibitor inhibit NSC3056 维生素E醋酸酯 DPP Dipeptidyl Peptidase NSC 3056 inhibitor